Literature DB >> 35804283

Clinical features and prognosis of isolated cardiac sarcoidosis diagnosed using new guidelines with dedicated FDG PET/CT.

Tomohisa Okada1, Naoto Kawaguchi1, Masao Miyagawa2, Marika Matsuoka1, Rami Tashiro1, Yuki Tanabe1, Tomoyuki Kido1, Toru Miyoshi3, Haruhiko Higashi3, Takeshi Inoue4, Hideki Okayama5, Osamu Yamaguchi3, Teruhito Kido1.   

Abstract

BACKGROUND: Diagnostic guidelines for isolated cardiac sarcoidosis (iCS) were first proposed in 2016, but there are few reports on the imaging and prognosis of iCS. This study aimed to evaluate the use of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) imaging in predicting iCS prognosis. METHODS AND
RESULTS: We retrospectively reviewed the clinical and imaging data of 306 consecutive patients with suspected CS who underwent FDG PET/CT with a dedicated preparation protocol and included 82 patients (55 with systemic sarcoidosis including cardiac involvement [sCS], 27 with iCS) in the study. We compared the FDG PET/CT findings between the two groups. We examined the relationship between the CS type and the rate of adverse cardiac events. The iCS group had a significantly lower target-to-background ratio than the sCS group (P = 0.0010). The event-free survival rate was significantly lower in the iCS group than the sCS group (log-rank test, P < 0.0001). iCS was identified as an independent prognostic factor for adverse events (hazard ratio 3.82, P = 0.0059).
CONCLUSION: iCS was an independent prognostic factor for adverse cardiac events in patients with CS. The clinical diagnosis of iCS based on FDG PET/CT and new guidelines may be important.
© 2022. The Author(s).

Entities:  

Keywords:  Isolated cardiac sarcoidosis; cardiac sarcoidosis; computed tomography; fluorodeoxyglucose positron emission tomography; prognosis

Year:  2022        PMID: 35804283     DOI: 10.1007/s12350-022-03034-0

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  3 in total

1.  The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool.

Authors:  Marc A Judson; Ulrich Costabel; Marjolein Drent; Athol Wells; Lisa Maier; Laura Koth; Hidenobu Shigemitsu; Dan A Culver; Jeffrey Gelfand; Dominique Valeyre; Nadera Sweiss; Elliott Crouser; Adam S Morgenthau; Elyse E Lower; Arata Azuma; Mami Ishihara; Shin-Ichiro Morimoto; Tetsuo Tetsuo Yamaguchi; Noriharu Shijubo; Jan C Grutters; Misha Rosenbach; Hui-Ping Li; Paola Rottoli; Yoshikazu Inoue; Antje Prasse; Robert P Baughman; The Wasog Sarcoidosis Organ Assessment Instrument Investigators
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2014-04-18       Impact factor: 0.670

2.  18F-FDG/13N-ammonia cardiac PET findings in ATTR cardiac amyloidosis.

Authors:  Kathleen A Young; Melissa Lyle; Andrew N Rosenbaum; Ian C Chang; Grace Lin; Melanie C Bois; Omar F Abou Ezzeddine; Hayan Jouni; Panithaya Chareonthaitawee; Suraj Kapa; Martha Grogan; Leslie T Cooper; Lori Blauwet; John P Bois
Journal:  J Nucl Cardiol       Date:  2022-01-27       Impact factor: 5.952

3.  Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan.

Authors:  K Iwai; T Tachibana; T Takemura; Y Matsui; M Kitaichi; Y Kawabata
Journal:  Acta Pathol Jpn       Date:  1993 Jul-Aug
  3 in total
  1 in total

1.  FDG uptake patterns in isolated and systemic cardiac sarcoidosis.

Authors:  Koichiro Kaneko; Michinobu Nagao; Atsushi Yamamoto; Akiko Sakai; Shuji Sakai
Journal:  J Nucl Cardiol       Date:  2022-10-03       Impact factor: 3.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.